According to results recently presented at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO), the addition of ixabepilone to Xeloda® (capecitabine) significantly improves outcomes compared with ixabepilone only in the treatment of metastatic breast cancer that does not respond to standard chemotherapy agents.
Metastatic breast cancer refers to cancer that has spread from the breast to distant sites in the body. Standard treatment for metastatic breast cancer typically includes chemotherapy with agents from the anthracycline or taxane groups. Unfortunately, some women with breast cancer do not respond to treatment with standard agents and are left with limited treatment options. This is referred to as resistant breast cancer. Because long-term outcomes for patients with resistant metastatic breast cancer remain suboptimal, researchers continue to evaluate novel agents that may improve survival for women with this disease.
Ixabepilone is an investigative chemotherapy agent, meaning it has not yet been approved by the United States Food and Drug Administration (FDA). However, it is in the last phase of clinical trials prior to FDA review.
Researchers from several medical institutions recently conducted a clinical trial evaluating the addition of ixabepilone to Xeloda in the treatment of metastatic breast cancer. This trial included 752 women with metastatic breast cancer that did not respond to anthracyclines or taxanes. Patients were treated with either Xeloda plus ixabepilone or Xeloda alone.
- Overall anticancer responses occurred in 35% of patients treated with Xeloda/ixabepilone compared with only 14% treated with Xeloda only.
- Progression-free survival was nearly six months for patients treated with Xeloda/ixabepilone compared with 4.2 months for those treated with Xeloda alone.
- At three months progression-free survival was 71% for patients treated with Xeloda/ixabepilone compared with 55% for those treated with Xeloda alone.
Understanding DNA Damage Response or DDR and Cancer Treatment
What is DNA Damage Response or DDR?
The researchers concluded that the addition of ixabepilone to Xeloda improves anticancer responses and progression-free survival compared with Xeloda alone in the treatment of metastatic breast cancer that does not respond to anthracyclines or taxanes.
Reference: Vahdat LT, Thomas E, Li R, et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer previously treated or resistant to an anthracycline and resistant to taxanes. Proceedings from the 2007 annual meeting of the American Society of Clinical Oncology. 2007;25:abstract 1006.
Related News:Ixabepilone Effective in Metastatic Breast Cancer That Doesn’t Respond to Standard Chemotherapy (7/6/2007)
Copyright © 2018 CancerConnect. All Rights Reserved.